Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
1.
Front Neuroendocrinol ; 73: 101136, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38670433

RESUMO

Nestorone® (segesterone acetate) is a progestin with a chemical structure closely related to progesterone with high affinity and selectivity for the progesterone receptor without significant interaction with other steroid receptors. It has been developed for female and male contraception and is FDA-approved in a first long-acting contraceptive vaginal system for female contraception. Its safety has been extensively demonstrated in both preclinical and clinical studies for contraceptive indications. Nestorone was found to display neuroprotective and neuroregenerative activity in animal models of various central nervous system diseases, including multiple sclerosis, stroke, and amyotrophic lateral sclerosis. Reviewed herein are neuroprotective and myelin- regenerating properties of Nestorone in various animal models and its translational potential as a therapeutic agent for debilitating neurological diseases for which limited therapeutic options are available (Table 1).


Assuntos
Fármacos Neuroprotetores , Norprogesteronas , Animais , Humanos , Norprogesteronas/farmacologia , Fármacos Neuroprotetores/farmacologia , Regeneração Nervosa/efeitos dos fármacos , Regeneração Nervosa/fisiologia , Feminino
2.
CNS Neurosci Ther ; 27(4): 464-469, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33369182

RESUMO

INTRODUCTION: We previously showed that Nestorone® (NES), a synthetic progestin structurally related to progesterone, stimulated remyelination of the corpus callosum in a Cuprizone (CUP) mouse model of demyelination in intact females by promoting replenishment with mature oligodendrocytes (OL) (Glia. 2015;63:104-117). Here, we further investigated the underlying mechanisms of this promyelinating effect. METHODS: We explored whether NES, applied subcutaneously through Alzet mini-osmotic pumps, regulates specific transcription factors involved in oligodendrocyte progenitor cell (OPC) proliferation and their differentiation into mature OL, using RT-qPCR and Western Blot analysis. RESULTS: Our present data show that in comparison to controls, a one-week treatment with NES, through Alzet mini-osmotic pumps, enhanced the production of three relevant transcription factor mRNAs encoding Olig2, Myt1, and Sox17. After 3 weeks, NES treatment reversed the effect of CUP on the levels of corresponding Olig2, Myt1, and Sox17 proteins. Moreover, in mice receiving NES + Estradiol (E2) co-treatment, levels of Olig2, Myt1, and Sox17 proteins did not change as compared to NES alone. CONCLUSION: NES alone or with E2 increased the levels of transcription factors, essential for myelin synthesis.


Assuntos
Doenças Desmielinizantes/tratamento farmacológico , Modelos Animais de Doenças , Bainha de Mielina/efeitos dos fármacos , Norprogesteronas/uso terapêutico , Remielinização/efeitos dos fármacos , Animais , Doenças Desmielinizantes/metabolismo , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Bainha de Mielina/metabolismo , Norprogesteronas/farmacologia , Remielinização/fisiologia
3.
Ann Clin Transl Neurol ; 6(7): 1302-1310, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31353848

RESUMO

OBJECTIVE: Progesterone is a potent neuromodulator that exerts effects on the brain through neurosteroids, progesterone receptors (PRs), and other molecules. Whether PR activation regulates seizures is not known. We determined whether PR activation increased seizure susceptibility. METHODS: Adult female rats that developed epilepsy following lithium-pilocarpine-induced status epilepticus (SE) were used. Seizures were recorded by continuous-video EEG and read by an individual blinded to the treatment of the animals. The animals were treated for a week with progesterone (50 mg/kg per day), and the effect of progesterone withdrawal on seizure frequency was assessed during the subsequent week. During the week of progesterone treatment, the animals were treated with PR antagonist RU-486 (10 mg/kg per day) or a vehicle control, which was administered 30 min before progesterone. In another set of animals, we determined the effect of the PR agonist Nestorone (3 mg/kg per day) on seizure frequency. The animals were treated with Nestorone or vehicle for a week, and seizure frequencies at baseline and during the treatment week were compared. RESULTS: Progesterone withdrawal induced twofold increase in seizures in 57% of animals (n = 14). RU-486 treatment in combination with progesterone, prevented this increase, and a smaller fraction of animals (17%) experienced withdrawal seizures (n = 13). The specific activation of PRs by Nestorone also increased the seizure frequency. Forty-six percent (n = 14) of Nestorone-treated animals experienced at least a 50% increase in seizures compared to only 9% of the vehicle-treated animals (n = 11). INTERPRETATION: PR activation increased seizure frequency in epileptic animals. Thus, PRs may be novel targets for treating catamenial epilepsy.


Assuntos
Progesterona/farmacologia , Receptores de Progesterona/metabolismo , Convulsões/metabolismo , Estado Epiléptico/metabolismo , Animais , Feminino , Mifepristona/farmacologia , Norprogesteronas/farmacologia , Pilocarpina/farmacologia , Progesterona/sangue , Progesterona/metabolismo , Ratos , Ratos Sprague-Dawley , Convulsões/induzido quimicamente , Convulsões/tratamento farmacológico , Estado Epiléptico/induzido quimicamente , Estado Epiléptico/tratamento farmacológico , Síndrome de Abstinência a Substâncias/metabolismo
4.
Andrology ; 7(6): 878-887, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-30969032

RESUMO

BACKGROUND: Novel male-based contraceptives are needed to broaden family planning choices. A progestin, Nestorone® (Nes) gel, plus a testosterone (T) gel suppresses sperm concentrations to levels associated with effective contraception in normal men. However, administration of two gels on different parts of the body daily is impractical. OBJECTIVE: Compare the effectiveness of daily application of a single, combined 8.3 mg Nes-62.5 mg T gel (Nes-T) vs. 62.7 mg T gel to suppress serum FSH and LH concentrations to ≤1.0 IU/L (a threshold associated with suppression of sperm concentrations to ≤1 million and effective contraception) and to compare the pharmacokinetics of serum Nes and T concentrations between the gel groups. DESIGN: We conducted a 28-day, double-blind, controlled trial of 44 healthy men randomized to daily Nes-T or T gel with measurement of hormones at baseline, treatment, and recovery and during 24-h pharmacokinetic studies on days 1 and 28 of treatment. RESULTS: Of the subjects who met pre-defined inclusion criteria, 84% of the Nes-T group suppressed serum gonadotropin concentrations to ≤1.0 IU/L at days 21-28 vs. 16.7% in the T group (p < 0.001). On day 1, Nes concentrations rose significantly above baseline by 2 h and continued to rise up to 24 h after Nes-T gel application. Nes concentrations were not detectable in the T group. Serum total T concentrations rose and were significantly higher in the T gel group compared to the Nes-T group at 24 h on day 1 and days 11, 14, and 21 (p < 0.01). There were no serious adverse events in either group. About 80% of the subjects reported satisfaction with both gels. CONCLUSION: Daily Nes-T gel effectively and safely suppresses serum gonadotropins and is acceptable to most men. It should be studied further in efficacy trials of hormonal male contraception.


Assuntos
Contraceptivos Hormonais/farmacologia , Anticoncepcionais Masculinos/farmacologia , Gonadotropinas/sangue , Norprogesteronas/farmacologia , Testosterona/farmacologia , Adolescente , Adulto , Contraceptivos Hormonais/farmacocinética , Anticoncepcionais Masculinos/farmacocinética , Método Duplo-Cego , Combinação de Medicamentos , Hormônio Foliculoestimulante/sangue , Contracepção Hormonal , Humanos , Hormônio Luteinizante/sangue , Masculino , Pessoa de Meia-Idade , Norprogesteronas/farmacocinética , Contagem de Espermatozoides , Espermatogênese/efeitos dos fármacos , Inquéritos e Questionários , Testosterona/farmacocinética , Congêneres da Testosterona/farmacologia , Adulto Jovem
5.
Brain Res ; 1719: 288-296, 2019 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-30244019

RESUMO

Progesterone (P4) exerts long-term neuroprotective effects in animal models of stroke, and P4 receptors play a crucial role in this neuroprotection. However, it currently remains unclear whether the activation of P4 receptors alone is sufficient to exert long-term neuroprotection because P4 exhibits other steroidogenic and GABAergic activities via several of its metabolites. Nestorone is a potent selective P4 receptor agonist without other steroidogenic and GABAergic activities. Therefore, we examined the effects of nestorone in adult male rats subjected to transient middle cerebral artery occlusion (MCAO). The dose-response relationship of nestorone showed that the 6-h post-ischemic administration of 10 µg/kg nestorone resulted in greater reductions in infarct sizes 48 h after MCAO than the other two doses tested (5 and 80 µg/kg), and this dose of nestorone significantly decreased astrocyte activation in the peri-infarct cortical region. Moreover, 10 µg/kg nestorone significantly prevented functional impairments on the 28th and 29th days and slightly reduced infarct size on the 30th day after MCAO. The present results suggest that the activation of P4 receptors alone is sufficient to exert neuroprotection against transient cerebral ischemia in adult male rats; therefore, nestorone is a promising agent in post-stroke treatment due to its potent progestational effects without other steroid-related activities.


Assuntos
Ataque Isquêmico Transitório/tratamento farmacológico , Ataque Isquêmico Transitório/metabolismo , Norprogesteronas/farmacologia , Animais , Isquemia Encefálica/tratamento farmacológico , Modelos Animais de Doenças , Infarto da Artéria Cerebral Média/complicações , Masculino , Neuroproteção/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Norprogesteronas/metabolismo , Progesterona/farmacologia , Ratos , Ratos Sprague-Dawley , Acidente Vascular Cerebral/tratamento farmacológico
6.
Menopause ; 25(10): 1138-1151, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-29846284

RESUMO

OBJECTIVE: Neurogenesis is the principal regenerative mechanism to sustain the plasticity potential in adult brains. Decreased neurogenesis parallels the cognition decline with aging, and has been suggested as a common hallmark in the progression of many neurodegeneration diseases. We previously reported that acute exposure to segesterone acetate (ST-1435; Nestorone), alone or in combination with 17ß-estradiol (E2), increased human neural stem cells proliferation and survival both in vitro and in vivo. The present study expanded our previous findings to investigate the more clinical related chronic exposure in combination with E2 on the regenerative capacity of adult brain. METHODS: To mimic the chronic contraception exposure in women, 3-month old female mice (n = 110) were treated with ST-1435, with or without co-administration of E2, for 4 weeks. Neural cell proliferation and survival, and oligodendrocyte generation were assessed. The involvement of insulin-like growth factor 1 signaling was studied. RESULTS: Our results demonstrated that chronic ST-1435 and E2 alone or in combination increased neurogenesis by a comparable magnitude, with minimum to no antagonistic or additive effects between ST-1435 and E2. In addition, chronic exposure of ST-1435 or ST-1435 + E2 stimulated oligodendrocyte generation, indicating potential elevated myelination. Insulin-like growth factor-1 (IGF-1) and IGF-1 receptor (IGF-1R) were also up-regulated after chronic ST-1435 and E2 exposure, suggesting the involvement of IGF-1 signaling as the potential underlined regulatory pathway transducing ST-1435 effect. CONCLUSION: These findings provide preclinical evidence and mechanistic insights for the development of ST-1435 as a neuroregenerative therapy to promote intrinsic regenerative capacity in female brains against aging and neurodegenerative disorders.


Assuntos
Estradiol/farmacologia , Lobo Frontal/citologia , Hipocampo/citologia , Neurogênese/efeitos dos fármacos , Norprogesteronas/farmacologia , Regeneração/efeitos dos fármacos , Envelhecimento/efeitos dos fármacos , Análise de Variância , Animais , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Disfunção Cognitiva/prevenção & controle , Modelos Animais de Doenças , Descoberta de Drogas , Quimioterapia Combinada , Estradiol/administração & dosagem , Estradiol/metabolismo , Feminino , Infusões Subcutâneas , Fator de Crescimento Insulin-Like I/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Células-Tronco Neurais/fisiologia , Doenças Neurodegenerativas/tratamento farmacológico , Norprogesteronas/administração & dosagem , Norprogesteronas/metabolismo , Oligodendroglia/fisiologia
7.
Contraception ; 97(3): 270-276, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-29097225

RESUMO

OBJECTIVES: To evaluate the effects of concurrent administration of three vaginal miconazole nitrate formulations on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol from a novel contraceptive vaginal ring (NES/EE CVR). STUDY DESIGN: This was an open-label, randomized, crossover, drug-drug interaction study conducted over three menstrual cycles in healthy women with regular menses. We compared systemic exposure to NES and EE by determining area under the curve (AUC8-21d) with CVR only and CVR with each miconazole treatment. Three different miconazole formulations (single-dose suppository, multiple-dose suppository or multiple-dose cream) were administered in a single dose on day 8 or multiple doses on days 8-10 after CVR insertion. We evaluated safety and tolerability of the CVR in the presence of antimycotic comedication. RESULTS: Forty-five participants were randomized, and 29 completed participation. Systemic exposure to NES and EE released from the CVR increased with single or multiple doses of miconazole suppositories but not with multiple-dose cream. The maximum EE geometric mean ratio (GMR) for AUC8-21d was 1.67 (1.51-1.86) for single-dose and 1.42 (1.21-1.66) for multiple-dose suppositories. By contrast, systemic exposure to NES and EE was comparable with and without miconazole cream (all GMRs and confidence intervals within 0.80 to 1.25). Adverse events (AEs) were similar with CVR only and with all miconazole treatment groups. There were no serious treatment-related AEs. CONCLUSIONS: Miconazole vaginal suppositories were associated with increased systemic levels of NES and EE, while systemic exposure with miconazole vaginal cream was comparable to no miconazole exposure. IMPLICATIONS: Coadministration of miconazole suppositories with the investigational NES/EE CVR led to higher systemic exposure of both hormones, while coadministration with miconazole cream did not affect hormone levels. Women utilizing the NES/EE CVR may be advised to use an oral formulation or miconazole cream rather than suppository to treat vaginal candidiasis.


Assuntos
Antifúngicos/farmacologia , Anticoncepcionais Femininos/farmacologia , Etinilestradiol/farmacologia , Miconazol/farmacologia , Norprogesteronas/farmacologia , Absorção Vaginal/efeitos dos fármacos , Administração Intravaginal , Adolescente , Adulto , Área Sob a Curva , Candidíase Vulvovaginal/tratamento farmacológico , Dispositivos Anticoncepcionais Femininos , Estudos Cross-Over , Interações Medicamentosas , Quimioterapia Combinada , Feminino , Humanos , Adulto Jovem
8.
PLoS One ; 11(10): e0164170, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27706226

RESUMO

Progestins used in contraception and hormone replacement therapy are synthetic compounds designed to mimic the actions of the natural hormone progesterone and are classed into four consecutive generations. The biological actions of progestins are primarily determined by their interactions with steroid receptors, and factors such as metabolism, pharmacokinetics, bioavailability and the regulation of endogenous steroid hormone biosynthesis are often overlooked. Although some studies have investigated the effects of select progestins on a few steroidogenic enzymes, studies comparing the effects of progestins from different generations are lacking. This study therefore explored the putative modulatory effects of progestins on de novo steroid synthesis in the adrenal by comparing the effects of select progestins from the respective generations, on endogenous steroid hormone production by the H295R human adrenocortical carcinoma cell line. Ultra-performance liquid chromatography/tandem mass spectrometry analysis showed that the fourth-generation progestins, nestorone (NES), nomegestrol acetate (NoMAC) and drospirenone (DRSP), unlike the progestins selected from the first three generations, modulate the biosynthesis of several endogenous steroids. Subsequent assays performed in COS-1 cells expressing human 3ßHSD2, suggest that these progestins modulate the biosynthesis of steroid hormones by inhibiting the activity of 3ßHSD2. The Ki values determined for the inhibition of human 3ßHSD2 by NES (9.5 ± 0.96 nM), NoMAC (29 ± 7.1 nM) and DRSP (232 ± 38 nM) were within the reported concentration ranges for the contraceptive use of these progestins in vivo. Taken together, our results suggest that newer, fourth-generation progestins may exert both positive and negative physiological effects via the modulation of endogenous steroid hormone biosynthesis.


Assuntos
17-Hidroxiesteroide Desidrogenases/metabolismo , Androstenos/farmacologia , Megestrol/farmacologia , Norpregnadienos/farmacologia , Norprogesteronas/farmacologia , Progestinas/farmacologia , Esteroides/biossíntese , 17-Hidroxiesteroide Desidrogenases/genética , Animais , Células COS , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Chlorocebus aethiops , Cromatografia Líquida , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Humanos , Espectrometria de Massas em Tandem
9.
Andrology ; 4(1): 4-12, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26453296

RESUMO

Despite numerous contraceptive options available to women, approximately half of all pregnancies in the United States and worldwide are unplanned. Women and men support the development of reversible male contraception strategies, but none have been brought to market. Herein we review the physiologic basis for male hormonal contraception, the history of male hormonal contraception development, currents agents in development as well as the potential risks and benefits of male hormonal contraception for men.


Assuntos
Anticoncepção/métodos , Anticoncepcionais Masculinos/farmacologia , Humanos , Masculino , Norprogesteronas/farmacologia , Testosterona/farmacologia , Congêneres da Testosterona/farmacologia
10.
Neuroscience ; 308: 51-63, 2015 Nov 12.
Artigo em Inglês | MEDLINE | ID: mdl-26349009

RESUMO

Wobbler mutant mice suffer from progressive motoneuron degeneration and glial cell reactivity in the spinal cord. To prevent development of these abnormalities, we employed Nestorone, a high-affinity progesterone receptor agonist endowed with neuroprotective, promyelinating and anti-inflammatory activities in experimental brain ischemia, preventing neuroinflammation and chemical degeneration. Five-month-old Wobbler mice (wr-/wr-) received s.c. injections of 200µg/day/mouse of Nestorone in vegetable oil or vehicle for 10days. Control NFR/NFR mice (background strain for Wobbler) received vehicle only. Vehicle-treated Wobblers showed typical spinal cord abnormalities, such as vacuolated motoneurons, decreased immunoreactive choline-acetyltransferase, decreased expression of glutamine synthase (GS), increased glial fibrillary acidic protein-positive (GFAP) astrogliosis and curved digits in forelimbs. These cell-specific abnormalities were normalized in Nestorone-treated Wobblers. In addition, vehicle-treated Wobblers showed Iba1+ microgliosis, high expression of the microglial marker CD11b mRNA and up-regulation of the proinflammatory markers TNFα and iNOS mRNAs. In Nestorone-treated Wobblers, Iba1+ microgliosis subsided, whereas CD11b, TNFα and iNOS mRNAs were down-regulated. NFκB mRNA was increased in Wobbler spinal cord and decreased by Nestorone, whereas expression of its inhibitor IκBα was increased in Nestorone-treated Wobblers compared to control mice and vehicle-treated Wobblers. In conclusion, our results showed that Nestorone restraining effects on proinflammatory mediators, microgliosis and astrogliosis may support neurons in their resistance against degenerative processes.


Assuntos
Anti-Inflamatórios/farmacologia , Doença dos Neurônios Motores/tratamento farmacológico , Fármacos Neuroprotetores/farmacologia , Norprogesteronas/farmacologia , Receptores de Progesterona/agonistas , Medula Espinal/efeitos dos fármacos , Animais , Astrócitos/efeitos dos fármacos , Astrócitos/metabolismo , Astrócitos/patologia , Modelos Animais de Doenças , Gliose/tratamento farmacológico , Gliose/patologia , Gliose/fisiopatologia , Masculino , Camundongos Mutantes , Microglia/efeitos dos fármacos , Microglia/metabolismo , Microglia/patologia , Doença dos Neurônios Motores/patologia , Doença dos Neurônios Motores/fisiopatologia , Neurônios Motores/efeitos dos fármacos , Neurônios Motores/metabolismo , Neurônios Motores/patologia , Neuroimunomodulação/efeitos dos fármacos , Neuroimunomodulação/fisiologia , Receptores de Progesterona/metabolismo , Medula Espinal/metabolismo , Medula Espinal/patologia , Resultado do Tratamento
11.
Gen Comp Endocrinol ; 200: 18-26, 2014 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-24530629

RESUMO

Progestin hormones stimulate sperm motility in teleosts but their mechanisms of action remain unclear. Preliminary results suggest that progestin upregulation of sperm motility in southern flounder and several other marine species is mediated through a sperm membrane progestin receptor with the characteristics of membrane progestin receptor alpha (mPRα, also known as Paqr7b). The hypothesis that mPRα has an important role in progestin regulation of southern flounder sperm motility and fertility was tested in the present study. The specific mPRα agonist, 10-ethenyl-19-norprogesterone (Org OD 02-0, 100nM), mimicked the stimulatory actions of the endogenous progestin, 17,20ß, 21-trihydroxy-4-pregnen-3-one (20ß-S, 100nM) on flounder sperm motility. The concentration of the mPRα protein on sperm plasma membranes was positively correlated to sperm motility as well as the responsiveness of sperm to progestin stimulation. Acute in vitro progestin treatment of sperm with high mPRα protein levels increased both sperm motility and fertilization success in strip spawning experiments. However, in vitro progestin treatments were ineffective on sperm with low receptor abundance. A single injection of the superactive gonadotropin-releasing hormone analog (LHRHa, 100µg/kg) increased sperm motility and fertilization success in strip spawning experiments 72h post-injection which was accompanied by an increase in mPRα protein concentrations on sperm plasma membranes. These results provide clear evidence that southern flounder sperm hypermotility is mediated through mPRα. Stimulatory G proteins, but not inhibitory G proteins, were identified in flounder sperm plasma membrane fractions. The finding that treatment of flounder sperm plasma membrane fractions with either 20ß-S or Org OD 02-0 increases cAMP levels suggests progestins stimulate flounder sperm motility by activating an mPRα/stimulatory G protein/membrane adenylyl cyclase pathway. A similar mechanism has been identified in Atlantic croaker, suggesting that the signaling pathway mediated by mPRα in sperm is highly conserved in advanced teleosts. Collectively, our results indicate that progestin-stimulation of flounder sperm hypermotility and fertility is dependent on a sufficient concentration of mPRα which can be upregulated by in vivo LHRHa treatments. These findings potentially have practical applications for enhancing the fertility of male flounder broodstock.


Assuntos
Membrana Celular/metabolismo , Fertilização/efeitos dos fármacos , Linguado/fisiologia , Progestinas/farmacologia , Receptores de Progesterona/metabolismo , Motilidade dos Espermatozoides/fisiologia , Animais , Membrana Celular/efeitos dos fármacos , Cortodoxona/análogos & derivados , Cortodoxona/farmacologia , AMP Cíclico/metabolismo , Subunidades alfa Gs de Proteínas de Ligação ao GTP/metabolismo , Hormônio Liberador de Gonadotropina/administração & dosagem , Hormônio Liberador de Gonadotropina/farmacologia , Humanos , Injeções , Masculino , Norprogesteronas/farmacologia , Motilidade dos Espermatozoides/efeitos dos fármacos , Espermatozoides/efeitos dos fármacos , Espermatozoides/metabolismo , Regulação para Cima/efeitos dos fármacos
12.
Andrology ; 1(6): 899-905, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24123845

RESUMO

Development of a male hormonal contraceptive has been challenging ascribable to the failure to adequately suppress spermatogenesis in 5-10% of men. Methods to identify incomplete suppressors early in treatment might identify men most responsive to male hormonal contraceptives. We hypothesized that serum hormone and gonadotropin concentrations after 4 weeks of transdermal treatment with testosterone and Nestorone in a contraceptive trial would be associated with suppression of sperm concentrations to <1 million/mL after 24 weeks. Indeed, luteinizing hormone or follicle-stimulating hormone concentrations greater than 1 IU/L after 4 weeks of transdermal testosterone/nestorone treatment were 97% sensitive for predicting failure to suppress spermatogenesis after 24 weeks of treatment. Serum nestorone concentrations were significantly associated with suppression, but serum testosterone concentrations were not. Early suppression of gonadotropins is associated with, but does not ensure, adequate suppression of spermatogenesis. This information may allow for rapid identification of non-responders in male hormonal contraceptive trials.


Assuntos
Norprogesteronas/farmacologia , Administração Cutânea , Adolescente , Adulto , Anticoncepcionais Masculinos/farmacologia , Hormônio Foliculoestimulante/sangue , Géis , Humanos , Hormônio Luteinizante/sangue , Masculino , Pessoa de Meia-Idade , Norprogesteronas/administração & dosagem , Norprogesteronas/sangue , Espermatogênese/efeitos dos fármacos , Testosterona/administração & dosagem , Testosterona/sangue , Testosterona/farmacologia
13.
Endocrinology ; 153(8): 3747-57, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22635678

RESUMO

Progesterone receptors (PR) are expressed throughout the brain. However, their functional significance remains understudied. Here we report a novel role of PR as crucial mediators of neuroprotection using a model of transient middle cerebral artery occlusion and PR knockout mice. Six hours after ischemia, we observed a rapid increase in progesterone and 5α-dihydroprogesterone, the endogenous PR ligands, a process that may be a part of the natural neuroprotective mechanisms. PR deficiency, and even haploinsufficiency, increases the susceptibility of the brain to stroke damage. Within a time window of 24 h, PR-dependent signaling of endogenous brain progesterone limits the extent of tissue damage and the impairment of motor functions. Longer-term improvement requires additional treatment with exogenous progesterone and is also PR dependent. The potent and selective PR agonist Nestorone is also effective. In contrast to progesterone, levels of the neurosteroid allopregnanolone, which modulates γ-aminobutyric acid type A receptors, did not increase after stroke, but its administration protected both wild-type and PR-deficient mice against ischemic damage. These results show that 1) PR are linked to signaling pathways that influence susceptibility to stroke, and 2) PR are direct key targets for both endogenous neuroprotection and for therapeutic strategies after stroke, and they suggest a novel indication for synthetic progestins already validated for contraception. Although allopregnanolone may not be an endogenous neuroprotective agent, its administration protects the brain against ischemic damage by signaling mechanisms not involving PR. Collectively, our data clarify the relative roles of PR and allopregnanolone in neuroprotection after stroke.


Assuntos
Receptores de Progesterona/metabolismo , Acidente Vascular Cerebral/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Masculino , Camundongos , Camundongos Knockout , Norprogesteronas/farmacologia , Norprogesteronas/uso terapêutico , Pregnanolona/farmacologia , Pregnanolona/uso terapêutico , Progesterona/farmacologia , Progesterona/uso terapêutico , Transdução de Sinais/efeitos dos fármacos , Acidente Vascular Cerebral/tratamento farmacológico , Acidente Vascular Cerebral/prevenção & controle
14.
Contraception ; 86(3): 231-7, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22445437

RESUMO

BACKGROUND: Discriminant analysis (DA) was performed on data of two combined hormonal contraceptives (CHC) differing in estrogen ratio to explore whether a combination of variables rather than a single variable distinguishes CHCs better. STUDY DESIGN: Data were used of a parallel study in premenopausal women treated for three cycles (21 days on, 7 days off) with a contraceptive vaginal ring delivering Nestorone and ethinyl estradiol (EE) or an oral contraceptive containing levonorgestrel and EE. DA was performed on the change from baseline (CFB) and the end-of-treatment values at 3 months for lipids, sex-hormone binding globulin (SHBG), C-reactive protein, angiotensinogen, blood pressure and hemostasis variables, and on the hemostasis variables only. RESULTS: For the complete set, the CFB for factor VII (FVII), SHBG and plasminogen (PLG), or end-of-treatment SHBG- and FVII level discriminated the treatments best. Maximal discrimination for the hemostasis data was by CFB for FVII and PLG or end-of-treatment FVII level. CONCLUSIONS: DA identifies differences between CHCs and may provide information on the factors associated with thrombotic risk.


Assuntos
Fatores de Coagulação Sanguínea/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Proteína C-Reativa/efeitos dos fármacos , Anticoncepcionais Orais Combinados/farmacologia , Etinilestradiol/farmacologia , Levanogestrel/farmacologia , Norprogesteronas/farmacologia , Globulina de Ligação a Hormônio Sexual/efeitos dos fármacos , Angiotensinogênio/efeitos dos fármacos , Angiotensinogênio/metabolismo , Proteína C-Reativa/metabolismo , HDL-Colesterol/efeitos dos fármacos , HDL-Colesterol/metabolismo , LDL-Colesterol/efeitos dos fármacos , LDL-Colesterol/metabolismo , Dispositivos Anticoncepcionais Femininos , Análise Discriminante , Combinação de Medicamentos , Feminino , Humanos , Risco , Globulina de Ligação a Hormônio Sexual/metabolismo , Trombose/induzido quimicamente , Trombose/epidemiologia , Triglicerídeos/metabolismo
15.
Maturitas ; 71(4): 345-53, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22364709

RESUMO

Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative with high biological activity at the progesterone receptor, a weak anti-androgenic effect, but with no binding to estrogen, glucocorticoid or mineralocorticoid receptors. At dosages of 1.5mg/day or more, NOMAC effectively suppresses gonadotropic activity and ovulation in women of reproductive age. Hemostasis, lipids and carbohydrate metabolism remain largely unchanged. In normal and cancerous human breast cells, NOMAC has shown favorable effects on estrogen metabolism. Like natural progesterone (but in contrast to some other synthetic progestogens), it does not appear stimulate the proliferation of cancerous breast cells. While there has been some experience of the use of NOMAC in combination with estrogens as a hormone replacement therapy, most of the data on the compound are reported in the context of its inclusion as a component of a new contraceptive pill comprising 2.5mg NOMAC combined with 1.5mg estradiol. Because of its strong endometrial efficacy, and due to its high antigonadotropic activity and long elimination half-life (about 50h), the contraceptive efficacy of the new pill is maintained even when dosages are missed. Furthermore, for the first time with a monophasic 24/4 regimen containing estradiol, cyclical stability can be achieved comparable with that obtained using pills containing ethinyl estradiol and progestogens like levonorgestrel or drospirenone. The addition of NOMAC to estradiol means that the beneficial effects of estrogen are not lost, which is of especial importance in relation to the cardiovascular system. On the basis both of its pharmacology and of studies performed during the development of the NOMAC/estradiol pill, involving some 4000 women in total, good long-term tolerability can be expected for NOMAC, although its safety profile is still to be fully ascertained, as the clinical endpoint studies are yet to be completed.


Assuntos
Anticoncepcionais Orais/farmacologia , Estrogênios/metabolismo , Megestrol/análogos & derivados , Ciclo Menstrual/efeitos dos fármacos , Ovulação/efeitos dos fármacos , Congêneres da Progesterona/farmacologia , Progestinas/farmacologia , Antagonistas de Androgênios/farmacologia , Endométrio/efeitos dos fármacos , Feminino , Gonadotropinas/metabolismo , Humanos , Megestrol/farmacologia , Norprogesteronas/farmacologia
16.
Endocrinology ; 152(10): 3820-31, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21828184

RESUMO

Enhancing the endogenous capacity of myelin repair is a major therapeutic challenge in demyelinating diseases such as multiple sclerosis. We found that progesterone and the synthetic 19-norprogesterone derivative 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione (Nestorone) promote the remyelination of axons by oligodendrocytes after lysolecithin-induced demyelination in organotypic cultures of cerebellar slices taken from postnatal rats or mice. The intracellular progesterone receptors (PR) mediate the proremyelinating actions of Nestorone, because they are not observed in slices from PR knockout mice. Notably, Nestorone was less efficient in heterozygous mice, expressing reduced levels of PR, suggesting PR haploinsufficiency in myelin repair. Using mice expressing the enhanced green fluorescent protein (EGFP) under the control of the proteolipid gene promoter, we showed that both progesterone and Nestorone strongly increased the reappearance of cells of the oligodendroglial lineage in the demyelinated slices. In contrast to Nestorone, the pregnane derivative medroxyprogesterone acetate had no effect. The increase in oligodendroglial cells by Nestorone resulted from enhanced NG2(+) and Olig2(+) oligodendrocyte progenitor cell (OPC) recruitment. In cocultures of lysolecithin-demyelinated cerebellar slices from wild-type mice apposed to brain stem slices of proteolipid gene promoter-EGFP mice, Nestorone stimulated the migration of OPC towards demyelinated axons. In this coculture paradigm, Nestorone indeed markedly increased the number of EGFP(+) cells migrating into the demyelinated cerebellar slices. Our results show that Nestorone stimulates the recruitment and maturation of OPC, two steps which are limiting for efficient myelin repair. They may thus open new perspectives for the use of progestins, which selectively target PR, to promote the endogenous regeneration of myelin.


Assuntos
Axônios/efeitos dos fármacos , Bainha de Mielina/efeitos dos fármacos , Norprogesteronas/farmacologia , Progesterona/farmacologia , Receptores de Progesterona/fisiologia , Animais , Axônios/fisiologia , Movimento Celular/efeitos dos fármacos , Masculino , Acetato de Medroxiprogesterona/farmacologia , Bainha de Mielina/fisiologia , Oligodendroglia/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
17.
Clin Exp Hypertens ; 31(4): 376-9, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19811365

RESUMO

19-nor-progesterone (19-nor-P) has the characteristics of a potent mineralocorticoid in adrenalectomized or salt-loaded rats and is capable of causing hypertension. In human placenta, progesterone is converted to 19-hydroxy-progesterone, a precursor of 19-nor-P. In some states of pregnancy hypertension, 19-nor-P may inhibit renal 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), thus allowing cortisol to bind to the mineralocorticoid receptor (MR). Therefore, we investigated the ability of 19-nor-P to inhibit human 11beta-HSD2. Fetal kidney cells (HEK 293) were transfected with human 11beta-HSD2 and incubated with increasing concentrations of 19-nor-P, labelled and unlabelled cortisol. Steroids were extracted, separated by TLC, and radioactivity was measured using a TLC scanner. 19-nor-P treatment did not significantly reduce 11beta-HSD2 activity (430 to 300 pmol/mg protein/h) in the range of tested concentrations. In conclusion, 19-nor-P did not inhibit human 11beta-HSD2 and seems not to be involved in human hypertension. Nevertheless, 19-nor-P may be converted by extra-adrenal tissues into 19-nor-deoxycorticosterone (DOC) or 19-nor-corticosterone, which are potent mineralocorticoids and may be involved in the pathogenesis of hypertension during pregnancy.


Assuntos
11-beta-Hidroxiesteroide Desidrogenase Tipo 2/metabolismo , Hidrocortisona/metabolismo , Norprogesteronas/metabolismo , 11-beta-Hidroxiesteroide Desidrogenase Tipo 2/antagonistas & inibidores , 11-beta-Hidroxiesteroide Desidrogenase Tipo 2/genética , Linhagem Celular , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Humanos , Hidrocortisona/farmacologia , Hipertensão/metabolismo , Rim/citologia , Rim/efeitos dos fármacos , Rim/metabolismo , Norprogesteronas/farmacologia , Transfecção
18.
J Clin Endocrinol Metab ; 94(7): 2313-20, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19366848

RESUMO

CONTEXT: Testosterone (T) plus progestin combinations are the most promising hormonal male contraceptives. Nestorone (NES), a progestin without estrogenic or androgenic activity, when combined with T may be an excellent candidate for male contraception. OBJECTIVE: Our objective was to determine the effect of transdermal NES gel alone or with T gel on gonadotropin suppression. DESIGN AND SETTING: The randomized, unblinded clinical trial was conducted at two academic medical centers. PARTICIPANTS: A total of 140 healthy male volunteers participated. INTERVENTIONS: One hundred subjects were randomized initially (20 per group) to apply NES gel 2 or 4 mg, T gel 10 g, or T gel 10 g plus NES gel 2 or 4 mg daily for 20 d. Because only about half of the subjects in T plus NES 4 mg group suppressed serum gonadotropins to 0.5 IU/liter or less (suboptimal suppression), two additional groups of 20 men were randomized to apply daily T gel 10 g plus NES gel 6 or 8 mg. MAIN OUTCOME VARIABLE: Suppression of serum LH and FSH concentrations to 0.5 IU/liter or less after treatment was the main outcome variable. RESULTS: A total of 119 subjects were compliant with gel applications with few study-related adverse events. NES alone reduced gonadotropins significantly but less than T gel alone. Combined T gel 10g plus NES gel 6 or 8 mg suppressed both serum gonadotropins to 0.5 IU/liter or less in significantly more men than either gel alone. CONCLUSION: Transdermal NES gel alone had gonadotropin suppression activity. Combined transdermal NES (6 or 8 mg) plus T gel demonstrated safe and effective suppression of gonadotropins, justifying a longer-term study of this combination for suppression of spermatogenesis.


Assuntos
Anticoncepção/métodos , Gonadotropinas/sangue , Norprogesteronas/farmacologia , Testosterona/farmacologia , Administração Cutânea , Adolescente , Adulto , Anticoncepção/efeitos adversos , Anticoncepcionais Masculinos/administração & dosagem , Anticoncepcionais Masculinos/efeitos adversos , Anticoncepcionais Masculinos/farmacologia , Regulação para Baixo/efeitos dos fármacos , Combinação de Medicamentos , Géis/administração & dosagem , Géis/efeitos adversos , Géis/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Norprogesteronas/administração & dosagem , Norprogesteronas/efeitos adversos , Congêneres da Progesterona/administração & dosagem , Congêneres da Progesterona/efeitos adversos , Congêneres da Progesterona/farmacologia , Globulina de Ligação a Hormônio Sexual/análise , Testosterona/administração & dosagem , Testosterona/efeitos adversos , Adulto Jovem
19.
BMC Cancer ; 8: 166, 2008 Jun 09.
Artigo em Inglês | MEDLINE | ID: mdl-18541028

RESUMO

BACKGROUND: Limited information is available on the effects of progestins on breast cancer progression and metastasis. Cell migration and invasion are central for these processes, and require dynamic cytoskeletal and cell membrane rearrangements for cell motility to be enacted. METHODS: We investigated the effects of progesterone (P), medroxyprogesterone acetate (MPA), drospirenone (DRSP) and nestorone (NES) alone or with 17beta-estradiol (E2) on T47-D breast cancer cell migration and invasion and we linked some of these actions to the regulation of the actin-regulatory protein, moesin and to cytoskeletal remodeling. RESULTS: Breast cancer cell horizontal migration and invasion of three-dimensional matrices are enhanced by all the progestins, but differences are found in terms of potency, with MPA being the most effective and DRSP being the least. This is related to the differential ability of the progestins to activate the actin-binding protein moesin, leading to distinct effects on actin cytoskeleton remodeling and on the formation of cell membrane structures that mediate cell movement. E2 also induces actin remodeling through moesin activation. However, the addition of some progestins partially offsets the action of estradiol on cell migration and invasion of breast cancer cells. CONCLUSION: These results imply that P, MPA, DRSP and NES alone or in combination with E2 enhance the ability of breast cancer cells to move in the surrounding environment. However, these progestins show different potencies and to some extent use distinct intracellular intermediates to drive moesin activation and actin remodeling. These findings support the concept that each progestin acts differently on breast cancer cells, which may have relevant clinical implications.


Assuntos
Androstenos/farmacologia , Neoplasias da Mama/patologia , Movimento Celular/efeitos dos fármacos , Acetato de Medroxiprogesterona/farmacologia , Norprogesteronas/farmacologia , Progesterona/farmacologia , Actinas/metabolismo , Neoplasias da Mama/metabolismo , Linhagem Celular Tumoral , Citoesqueleto/efeitos dos fármacos , Citoesqueleto/metabolismo , Estradiol/farmacologia , Humanos , Proteínas dos Microfilamentos/metabolismo , Invasividade Neoplásica , Transdução de Sinais/efeitos dos fármacos
20.
J Steroid Biochem Mol Biol ; 110(1-2): 39-47, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18395441

RESUMO

The recent identification of tetrahydrogestrinone (THG), a non-marketed designer androgen used for sports doping but previously undetectable by established mass spectrometry-based urine drug screens, and its production by a facile chemical modification of gestrinone has raised concerns about the risks of developing designer androgens from numerous marketed progestins. We therefore have used yeast-based in vitro androgen and progesterone bioassays to conduct a structure-activity study assessing the intrinsic androgenic potential of commercially available progestins and their derivatives, to identify those compounds or structures with the highest risk of forming a basis for such misapplication. Progestins had a wide range of androgenic bioactivity that was not reliably predicted for individual steroids by their progestin bioactivity. 17alpha-Hydroxyprogesterone and 19-norprogesterone derivatives with their bulky 17beta-substituents were strong progestins but generally weak androgens. 17alpha-Ethynylated derivatives of testosterone, 19-nortestosterone and 18-methyl-19-nortestosterone such as gestrinone, ethisterone, norethisterone and norgestrel had the most significant intrinsic androgenicity of all the commercially marketed progestins. Facile chemical modification of the 17alpha-ethynyl group of each of these progestins produces 17alpha-methyl, ethyl and allyl derivatives, including THG and norbolethone, which further enhanced androgenic bioactivity. Thus by using the rapid and sensitive yeast bioassay we have screened a comprehensive set of progestins and associated structures and identified the ethynylated testosterone, 19-nortestosterone and 18-methyl-19-nortestosterone derivatives as possessing the highest risk for abuse and potential for conversion to still more potent androgens. By contrast, modern progestins such as progesterone, 17alpha-hydroxyprogesterone and 19-norprogesterone derivatives had minimal androgenic bioactivity and pose low risk.


Assuntos
Androgênios/metabolismo , Progestinas/metabolismo , Leveduras/metabolismo , Androgênios/química , Androgênios/farmacologia , Bioensaio/métodos , Relação Dose-Resposta a Droga , Etisterona/química , Etisterona/metabolismo , Etisterona/farmacologia , Gestrinone/química , Gestrinone/metabolismo , Gestrinone/farmacologia , Estrutura Molecular , Noretindrona/química , Noretindrona/metabolismo , Noretindrona/farmacologia , Norgestrel/química , Norgestrel/metabolismo , Norgestrel/farmacologia , Norpregnenos/química , Norpregnenos/metabolismo , Norpregnenos/farmacologia , Norprogesteronas/química , Norprogesteronas/metabolismo , Norprogesteronas/farmacologia , Progestinas/química , Progestinas/farmacologia , Receptores Androgênicos/metabolismo , Receptores de Progesterona/metabolismo , Relação Estrutura-Atividade , Leveduras/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA